The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1529
Safinamide (Xadago) for Parkinson's Disease
The full article is available to subscribers Subscriber Login   

The FDA has approved the monoamine oxidase type B (MAO-B) inhibitor safinamide (Xadago – US Worldmeds) as an adjunct to levodopa/carbidopa for management of "off" episodes in patients with Parkinson's disease (PD). It is the first reversible MAO-B inhibitor to be approved for this indication. Selegiline (Eldepryl, and others) and rasagiline (Azilect, and generics), two irreversible MAO-B inhibitors, have been used alone and as adjuncts to levodopa/carbidopa for many years. Safinamide is not approved for use as monotherapy.

STANDARD TREATMENT — Levodopa combined with carbidopa is still the most effective treatment for symptoms of PD, but motor fluctuations and dyskinesia can be problematic as the disease advances and higher doses are required.1-3 Adding a dopamine agonist, catechol O-methyltransferase (COMT) inhibitor, or MAO-B inhibitor can reduce ... more       Show References Hide References

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Immediate Online access to current issue and archives from 1988 to the present
  • Mobile access to our mobile site and free apps for iOS, Android and Kindle
  • FREE online per issue CME/CE
Free trial offer
3 Free Issues of The Medical Letter on Drugs and Therapeutics mailed to your home or office PLUS online access.
Try a Free Trial Subscription
Purchase this article:
Title: Safinamide (Xadago) for Parkinson's Disease
Article code: 1529c
 Electronic, downloadable article - $25